Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Chonbuk National University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the pharmacokinetics of single oral dose of Amitriptyline hydrochloride film-coated tablet 10mg & 25mg
Randomized, Single dose, 2-way crossover, Open Study to compare the pharmacokinetics profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg after a single oral administration in healthy male volunteers
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A Group | Experimental |
|
|
| B Group | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DWETR10 | Drug | Amitriptyline hydrochloride 10mg(DWETR10) single dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUClast and AUCinf | Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma | Up to 72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax | Maximum Concentration(Cmax) of amitryptyline in plasma | Up to 72 hours |
| Tmax | Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma |
Not provided
Inclusion Criteria:
a healthy adult male within the range of 19 to 50 years old at the time of screening
one with weight of more than 55kg, in the range of IBW 20%
one who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Min-Gul Kim, MD, PhD | Chonbuk National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chonbuk National University Hospital. | Jeonju | Jeollabuk-do | 561-712 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25308868 | Derived | Nam Y, Lim CH, Lee HS, Chung SJ, Chung YH, Shin YK, Kim MG, Sohn UD, Kim HC, Jeong JH. Single-dose, randomized, open-label, 2-way crossover study of the pharmacokinetics of amitriptyline hydrochloride 10- and 25-mg tablet in healthy male Korean volunteers. Clin Ther. 2015 Feb 1;37(2):302-10. doi: 10.1016/j.clinthera.2014.09.010. Epub 2014 Oct 11. |
Not provided
Not provided
15 participants recruited ; 12 screened, 3 excluded (2 did not meet inclusion criteria and 1 refused participation)
Participants recruited from a specialty clinic at a hospital, Korea between July 2011 and August 2011
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | A Group | Etravil tablet 10mg once daily in first intervention period and Etravil tablet 25mg once daily in second intervention period (10days washout period, Intervention period : 1day) |
| FG001 | B Group | Etravil tablet 25mg once daily in first intervention period and Etravil tablet 10mg once daily in second intervention period (10days washout period, Intervention period : 1day) |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st Administration |
| |||||||||||||
| 2nd Administration |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | A Group | Etravil tablet 10mg once daily in first intervention period and Etravil tablet 25mg once daily in second intervention period (10days washout period, Intervention period : 1day) |
| BG001 | B Group |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | AUClast and AUCinf | Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma | Posted | Mean | Standard Deviation | ng*hr/mL | Up to 72 hours |
|
About a month
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Etravil 10mg Group | Amitryptyline hydrochloride 10mg administration Group |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | MedDRA 13.1 | Systematic Assessment |
When collecting blood samples, few subjects were drawn blood later than that stated in protocol for about 1 ~ 2 minutes where results may not be effected.
One of the subjects came in late for Post-study visit for about 4~6 days.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Cheol-Hee Lim. Clinical Research Manager (CRM) | Dong Wha Pharm. Co. Ltd. | +82-2-2021-9300 | 551 | cheolhee.lim@dong-wha.co.kr |
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| D004775 | Enuresis |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DWETR25 | Drug | Amitriptyline hydrochloride 25mg(DWETR25) single dose |
|
|
| Up to 72 hours |
| t1/2 | Terminal half-time(t1/2) of Amitryptyline in Plasma | Up to 72 hours |
| NOT COMPLETED |
|
Etravil tablet 25mg once daily in first intervention period and Etravil tablet 10mg once daily in second intervention period (10days washout period, Intervention period : 1day)
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
| Secondary | Cmax | Maximum Concentration(Cmax) of amitryptyline in plasma | Posted | Mean | Standard Deviation | ng/mL | Up to 72 hours |
|
|
|
| Secondary | Tmax | Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma | Posted | Mean | Standard Deviation | hour | Up to 72 hours |
|
|
|
| Secondary | t1/2 | Terminal half-time(t1/2) of Amitryptyline in Plasma | Posted | Mean | Standard Deviation | hour | Up to 72 hours |
|
|
|
| 0 |
| 12 |
| 2 |
| 12 |
| EG001 | Etravil 25mg Group | Amitryptyline hydrochloride 25mg administration Group | 0 | 12 | 2 | 12 |
| Asthenia | General disorders | MedDRA 13.1 | Systematic Assessment |
|
Not provided
Not provided
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D019960 | Elimination Disorders |
| D001523 | Mental Disorders |